COMBIVET
  • Home
    • About us
    • Combivet Ethics Committee
    • Contact
  • Team
  • Research
    • ​Host-Pathogen Interactions and Disease Biomarkers Discovery >
      • Research project I
      • Research project II
    • Infertility and Subfertility >
      • Research project III
      • Research project IV
      • Research project V
    • ​Food, Feed & Health >
      • Research project VI
    • Non - Communicable Diseases and Cancer >
      • Research project VII
      • Research project VIII
  • Publications
  • NEWS & EVENTS
    • News
    • Seminars
    • Events >
      • Annual conference 2024
      • Research school 2024
      • Ethics debate 2023
      • Research school 2023
      • Annual conference 2023
      • Symposium 2023
      • Conference 2022
      • Summer School 2022
      • One Health Estonia 2022
      • CANLEISH/COMBIVET joint event 2022
  • University of Life Sciences
  • EUP AH&W

Olavi Reinsalu

Junior Research Fellow in Biomedical Technology, Faculty of Science and Technology, University of Tartu,  Tartu, Estonia
Olavi Reinsalu received his diplomas for his bachelor’s and master’s degree in the curriculum of gene technology at the University of Tartu in 2012 and 2015, respectively. For the research of his master’s thesis he studied virus-like particles carrying melanoma antigens. After graduation he worked for three years as a researcher in University of Tartu and Competence Center of Health Technologies developing a bovine fluorescence in situ hybridization technique as part of a R&D project for agricultural enterprises. Starting from fall 2018 he became a doctoral student in University of Tartu studying in the curriculum of technology and engineering specializing in biomedical technology. His PhD study is continuation of his research from master’s and is also about extracellular vesicles and virus-like particles carrying melanoma antigens.


Cancer-testis antigen MAGE-A4 carrying EVs - tools for cancer theranostics

Cancer-testis antigens (CTAs) are proteins that are normally expressed mainly in testis but aberrantly in various tumours. It has been shown that CTAs contribute to tumorigenic processes and, as antigens, these proteins are known to induce anticancer immune responses. MAGE-A4, a known CTA, is a soluble cytoplasmic or nuclear protein with a partially disordered structure. Although its exact cellular function has largely remained elusive, MAGE-A4 has been shown to have tumorigenic and antitumorigenic properties. We have discovered that MAGE-A4 is incorporated into virus-like particles and native extracellular vesicles (EVs) released by cells that express it. The artificially induced VLPs and natively emerged EVs expose MAGE-A4 to their outer surface, which is considered a fascinating phenomenon considering the intracellular localization of MAGE-A4. In the speech, MAGE-A4 carrying vesicles will be described showing their potential for anti-cancer therapeutic and diagnostic techniques. 

​COMBIVET

MENU
ADDRESS
Estonian University of Life Sciences
Institute of Veterinary Medicine and Animal Sciences

​
Picture
Home
Research
Publications
News & Events
University of Life Sciences
Kreutzwaldi 62,
Tartu 51006,
tel/fax 7313 706
​Estonia
Contact us
Picture
​This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 857418.
  • Home
    • About us
    • Combivet Ethics Committee
    • Contact
  • Team
  • Research
    • ​Host-Pathogen Interactions and Disease Biomarkers Discovery >
      • Research project I
      • Research project II
    • Infertility and Subfertility >
      • Research project III
      • Research project IV
      • Research project V
    • ​Food, Feed & Health >
      • Research project VI
    • Non - Communicable Diseases and Cancer >
      • Research project VII
      • Research project VIII
  • Publications
  • NEWS & EVENTS
    • News
    • Seminars
    • Events >
      • Annual conference 2024
      • Research school 2024
      • Ethics debate 2023
      • Research school 2023
      • Annual conference 2023
      • Symposium 2023
      • Conference 2022
      • Summer School 2022
      • One Health Estonia 2022
      • CANLEISH/COMBIVET joint event 2022
  • University of Life Sciences
  • EUP AH&W